Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

BACKGROUND: It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of RCC...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yoshimura, K, Minami, T, Nozawa, M, Uemura, H
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3619266/
https://ncbi.nlm.nih.gov/pubmed/23470466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.90
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky